H. Lundbeck A/S (VIE:LUNA)
Austria · Delayed Price · Currency is EUR | Market Cap | 5.23B +3.9% |
| Revenue (ttm) | 3.30B +11.9% |
| Net Income | 427.40M +1.6% |
| EPS | 0.43 +1.5% |
| Shares Out | n/a |
| PE Ratio | 12.23 |
| Forward PE | 6.50 |
| Dividend | 0.15 (3.39%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 4.540 |
| Previous Close | 4.555 |
| Day's Range | 4.525 - 4.560 |
| 52-Week Range | 3.125 - 5.320 |
| Beta | n/a |
| RSI | 52.14 |
| Earnings Date | May 13, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...